Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2011, Article ID 543272, 5 pages
http://dx.doi.org/10.1155/2011/543272
Review Article

Review of Small Cell Carcinomas of the Prostate

1Department of Pathology, Escola Paulista de Medicina Universidade Federal de São Paulo (UNIFESP), Rua Botucatu 740, São Paulo, SP, Brazil
2Presidente Dutra University Hospital, Federal University of Maranhao, São Luis, MA, Brazil
3Departments of Pathology and Urology, Cancer Institute of Ceara, CE, Brazil

Received 1 March 2011; Revised 16 May 2011; Accepted 30 May 2011

Academic Editor: Dengfeng Cao

Copyright © 2011 P. Furtado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Wenk, B. S. Bhagavan, and R. Levy, “Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia,” Cancer, vol. 40, no. 2, pp. 773–778, 1977. View at Google Scholar · View at Scopus
  2. A. J. Evans, P. A. Humphrey, J. Belani, T. H. van der Kwast, and J. R. Srigley, “Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer,” American Journal of Surgical Pathology, vol. 30, no. 6, pp. 684–693, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Giordano, T. Tolonen, S. Hirsimäki, and V. Kataja, “A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate,” International Urology and Nephrology, vol. 42, no. 3, pp. 683–687, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. H. Lim, M. J. Huang, S. Yang, R. K. Hsieh, and J. Lin, “Primary carcinoid tumor of prostate presenting with bone marrow metastases,” Urology, vol. 65, no. 1, p. 174, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Reyes and C. A. Moran, “Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate,” Archives of Pathology & Laboratory Medicine, vol. 128, no. 12, pp. e166–168, 2004. View at Google Scholar · View at Scopus
  6. W. Wang and J. I. Epstein, “Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases,” American Journal of Surgical Pathology, vol. 32, no. 1, pp. 65–71, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Zarkovic, J. Masters, and L. Carpenter, “Primary carcinoid tumour of the prostate,” Pathology, vol. 37, no. 2, pp. 184–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Rekhtman, “Neuroendocrine tumors of the lung,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 11, pp. 1628–1638, 2010. View at Google Scholar
  9. F. Abbas, F. Civantos, P. Benedetto, and M. S. Soloway, “Small cell carcinoma of the bladder and prostate,” Urology, vol. 46, no. 5, pp. 617–630, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Alberti, “Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features,” Giornale di Chirurgia, vol. 31, no. 11-12, pp. 568–574, 2010. View at Google Scholar
  11. J. H. Yoo, J. H. Lee, E. K. Kim, Y. K. Hong, Y. Lee, and H. C. Jeong, “Prostatic metastasis of large cell neuroendocrine carcinoma of the lung,” Respirology, vol. 14, no. 5, pp. 772–775, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. Mazzucchelli, D. Morichetti, A. Lopez-Beltran et al., “Neuroendocrine tumours of the urinary system and male genital organs: clinical significance,” BJU International, vol. 103, no. 11, pp. 1464–1470, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K. Brownback, J. Renzulli, R. DeLellis, and J. Myers, “Small-cell prostate carcinoma: a retrospective analysis of five newly reported cases,” Indian Journal of Urology, vol. 25, no. 2, pp. 259–263, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. E. Stein, Z. Bernstein, U. Abacioglu et al., “Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications—A retrospective study of 30 patients from the rare cancer network,” American Journal of the Medical Sciences, vol. 336, no. 6, pp. 478–488, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Abrahamsson, “Neuroendocrine differentiation in prostatic carcinoma,” Prostate, vol. 39, no. 2, pp. 135–148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Di Sant'Agnese and A. T. K. Cockett, “Neuroendocrine differentiation in prostatic malignancy,” Cancer, vol. 78, no. 2, pp. 357–361, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Yao, R. Madeb, P. Bourne et al., “Small cell carcinoma of the prostate: an immunohistochemical study,” American Journal of Surgical Pathology, vol. 30, no. 6, pp. 705–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Segawa, T. Inamoto, N. Ibuki et al., “Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report,” Acta Urologica Japonica, vol. 56, no. 1, pp. 49–54, 2010. View at Google Scholar · View at Scopus
  19. A. Sella, M. Konichezky, D. Flex, A. Sulkes, and J. Baniel, “Low PSA metastatic androgen-independent prostate cancer,” European Urology, vol. 38, no. 3, pp. 250–254, 2000. View at Google Scholar · View at Scopus
  20. J. E. Oesterling, C. G. Hauzeur, and G. M. Farrow, “Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients,” Journal of Urology, vol. 147, no. 3, part 2, pp. 804–807, 1992. View at Google Scholar · View at Scopus
  21. L. O. Reis, L. F. Vieira, E. L. Zani, F. Denardi, L. C. De Oliveira, and U. Ferreira, “Assessment of serum chromogranin—A as prognostic factor in high-risk prostate cancer,” Journal of Investigative Medicine, vol. 58, no. 8, pp. 957–960, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. A. Sciarra, F. Di Silverio, A. M. Autran et al., “Distribution of high chromogranin a serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma,” Urologia Internationalis, vol. 82, no. 2, pp. 147–151, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. Alessandro, G. Vincenzo, A. G. Maria et al., “Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 625–632, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Isshiki, K. Akakura, A. Komiya, H. Suzuki, N. Kamiya, and H. Ito, “Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer,” Journal of Urology, vol. 167, no. 2, part 1, pp. 512–515, 2002. View at Google Scholar · View at Scopus
  25. D. P. Sarma and T. G. Weilbaecher, “Small-cell carcinoma of prostate,” Urology, vol. 33, no. 4, pp. 332–335, 1989. View at Google Scholar · View at Scopus
  26. E. A. Turbat-Herrera, G. A. Herrera, I. Gore, R. L. Lott, W. E. Grizzle, and J. M. Bonnin, “Neuroendocrine differentiation in prostatic carcinomas. A retrospective autospy study,” Archives of Pathology and Laboratory Medicine, vol. 112, no. 11, pp. 1100–1105, 1988. View at Google Scholar · View at Scopus
  27. M. G. Weaver, F. W. Abdul-Karim, and J. R. Srigley, “Paneth cell-like change and small cell carcinoma of the prostate: two divergent forms of prostatic neuroendocrine differentiation,” American Journal of Surgical Pathology, vol. 16, no. 10, pp. 1013–1016, 1992. View at Google Scholar · View at Scopus
  28. Y. Miyoshi, H. Uemura, K. Kitami, Y. Satomi, Y. Kubota, and M. Hosaka, “Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy,” BJU International, vol. 88, no. 9, pp. 982–983, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tanaka, Y. Suzuki, K. Takaoka et al., “Progression of prostate cancer to neuroendocrine cell tumor,” International Journal of Urology, vol. 8, no. 8, pp. 431–436, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. Simon, P. A. di Sant'Agnese, L. S. Huang et al., “CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers,” Human Pathology, vol. 40, no. 2, pp. 252–258, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. C. L. Owens, J. I. Epstein, and G. J. Netto, “Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 4, pp. 599–603, 2007. View at Google Scholar
  32. A. Y. Chuang, A. M. DeMarzo, R. W. Veltri, R. B. Sharma, C. J. Bieberich, and J. I. Epstein, “Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma,” American Journal of Surgical Pathology, vol. 31, no. 8, pp. 1246–1255, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. M. Varma and B. Jasani, “Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature,” Histopathology, vol. 47, no. 1, pp. 1–16, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. O. Hameed and P. A. Humphrey, “Immunohistochemistry in diagnostic surgical pathology of the prostate,” Seminars in Diagnostic Pathology, vol. 22, no. 1, pp. 88–104, 2005. View at Publisher · View at Google Scholar
  35. A. van der Gaast, J. Verweij, A. S. Planting, G. Stoter, and S. C. Henzen-Logmans, “The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 3, pp. 181–185, 1996. View at Publisher · View at Google Scholar
  36. D. E. Hansel, M. Nakayama, J. Luo et al., “Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate,” Prostate, vol. 69, no. 6, pp. 603–609, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. C. C. Guo, J. Y. Dancer, Y. Wang et al., “TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate,” Human Pathology, vol. 42, no. 1, pp. 11–17, 2011. View at Publisher · View at Google Scholar · View at PubMed
  38. T. L. Lotan, N. S. Gupta, W. Wang et al., “ERG gene rearrangements are common in prostatic small cell carcinomas,” Modern Pathology, vol. 24, no. 6, pp. 820–828, 2011. View at Publisher · View at Google Scholar · View at PubMed
  39. S. Tai, Y. Sun, J. M. Squires et al., “PC3 is a cell line characteristic of prostatic small cell carcinoma,” Prostate. In press. View at Publisher · View at Google Scholar · View at PubMed
  40. H. Aoki, S. Ishidoya, A. Ito, M. Endoh, T. Shimazui, and Y. Arai, “Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate,” International Journal of Urology, vol. 13, no. 9, pp. 1254–1258, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. J. Köllermann and B. Helpap, “Neuroendocrine differentiation and short-term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression,” European Urology, vol. 40, no. 3, pp. 313–317, 2001. View at Publisher · View at Google Scholar
  42. C. N. Papandreou, D. D. Daliani, P. F. Thall et al., “Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate,” Journal of Clinical Oncology, vol. 20, no. 14, pp. 3072–3080, 2002. View at Publisher · View at Google Scholar
  43. D. Leibovici, P. E. Spiess, P. K. Agarwal et al., “Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level,” Cancer, vol. 109, no. 2, pp. 198–204, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. M. E. Spieth, Y. G. Lin, and T. T. Nguyen, “Diagnosing and treating small-cell carcinomas of prostatic origin,” Clinical Nuclear Medicine, vol. 27, no. 1, pp. 11–17, 2002. View at Publisher · View at Google Scholar
  45. J. R. Mackey, H. J. Au, J. Hugh, and P. Venner, “Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival,” Journal of Urology, vol. 159, no. 5, pp. 1624–1629, 1998. View at Google Scholar
  46. J. E. Brammer, P. Lulla, and G. R. Lynch, “Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate,” International Journal of Clinical Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Feng, I. U. Agoulnik, A. Truong et al., “Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis,” Endocrine-Related Cancer, vol. 17, no. 4, pp. 1021–1033, 2010. View at Publisher · View at Google Scholar · View at PubMed